Table 3. Patient Characteristics (n = 78).

Characteristic	Value
Age: median (range), yr	44 (15-65)
Gender: Male/female	53/25
Primary refractory tumor/poor-risk or refractory relapse	57%/43%
No. prior chemotherapy lines, median, (range)	3 (1-7)
Prior radiotherapy, %	43%
Disease status at HDC: CR/PR/no response, %	52%/22%/26%
PD at HDC	17%
Diagnoses
DLCL	52
Variants
NOS	39
T cell rich	4
Primary CNS	2
Anaplastic	2
Plasmablastic	2
Transformed	3
Double hit (% of DLCL)	10 (19%)
Cell of origin
Germinal center	15
Activated B cell	12
Primary mediastinal	8
Not determined	17
Primary refractory (%) (induction PR/induction failure)	26 (50%) (14/12)
Relapsed (%)	26 (50%)
First relapse (%)	13 (25%)
Length of CR1: <12months/≥12 months	6/7
Secondary IPI: 0-1/2/>3	6/6/1
Second relapse or later (%)	13 (25%)
Hodgkin's	20
Primary refractory (% of Hodgkin's)	13 (65%)
Poor-risk relapse	7
First relapse (%)	1 (CR1 ≤12 months) (5%)
≥Second relapse (%)	6 (30%)
Extranodal disease at relapse/PD	12
Bulky tumor at relapse/PD	11
B symptoms at relapse/PD	2
T-NHL	6
Histology (PTCL NOS/AITL/ALCL/NK-T)	2/2/1/1
Primary refractory/relapsed	4/2

PR indicates partial response; NOS, not otherwise specified; CNS, central nervous system; PTCL, peripheral T-cell lymphoma; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large-cell lymphoma; NK-T, natural killer T cell.